{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and docket_id = \"FDA-1981-N-0114\" sorted by posted_date descending", "rows": [["FDA-1981-N-0114-0030", "FDA", "FDA-1981-N-0114", "Letter to Morgan, Lewis & Bockius, LLP from FDA CDER", "Other", "Letter(s)", "2020-11-02T05:00:00Z", 2020, 11, "2020-11-02T05:00:00Z", null, "2020-11-02T18:17:24Z", null, 0, 0, "0900006484946740"], ["FDA-1981-N-0114-0016", "FDA", "FDA-1981-N-0114", "List of References - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:17:32Z", null, 0, 0, "0900006480ab41ce"], ["FDA-1981-N-0114-0017", "FDA", "FDA-1981-N-0114", "Reference  3 - \"Comment No. C4, 1981N-114A\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:18:11Z", null, 0, 0, "0900006480ab4260"], ["FDA-1981-N-0114-0020", "FDA", "FDA-1981-N-0114", "Reference 11 - \"Comment No. LET19, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:19:59Z", null, 0, 0, "0900006480ab46ef"], ["FDA-1981-N-0114-0004", "FDA", "FDA-1981-N-0114", "Nonprescription Drug Manufacturers Association (NDMA) to FDA/CDER, October 7, 1991 - Letter", "Other", "LET-Letter", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", null, "2010-03-04T23:56:07Z", null, 0, 0, "09000064805b0534"], ["FDA-1981-N-0114-0006", "FDA", "FDA-1981-N-0114", "FDA/CDER to Nonprescription Drug Manufacturers Association (NDMA) - Letter", "Other", "LET-Letter", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", null, "2010-03-04T23:56:11Z", null, 0, 0, "09000064805b053b"], ["FDA-1981-N-0114-0005", "FDA", "FDA-1981-N-0114", "FDA/CDER and the National Consumers League (NCL), October 9, 1981 - Memorandum of Telephone Conversation", "Other", "MT-Memorandum of Telephone Conversation", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", null, "2010-03-04T23:56:09Z", null, 0, 0, "09000064805b0535"], ["FDA-1981-N-0114-0003", "FDA", "FDA-1981-N-0114", "Topical Acne Drug Products For Over-The-Counter Human Use; Amendment of Tenative Final Monograph; Reopening of Comment Period", "Notice", "NPR-Notice of Proposed Rule-Making", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", "1991-11-08T04:59:59Z", "2010-03-04T23:56:06Z", null, 0, 0, "09000064805b0536"], ["FDA-1981-N-0114-0021", "FDA", "FDA-1981-N-0114", "Reference 12 - \"Comment No. LET20, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:20:47Z", null, 0, 0, "0900006480ab46f0"], ["FDA-1981-N-0114-0029", "FDA", "FDA-1981-N-0114", "Reference 22 - \"FDA Labeling Cost Model, Final Report\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:25:20Z", null, 0, 0, "0900006480ab4875"], ["FDA-1981-N-0114-0007", "FDA", "FDA-1981-N-0114", "FDA/CDER and Nonprescription Drug Manufacturers Association (NDMA) Meeting, July 27, 1992 re Benzoyl Peroxide-Ultra Violet Light Testing Protocol - Memorandum of Meeting", "Other", "MM-Memorandum of Meeting", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", null, "2010-03-04T23:56:12Z", null, 0, 0, "09000064805b053c"], ["FDA-1981-N-0114-0027", "FDA", "FDA-1981-N-0114", "Reference 18 - \"Comment No. C1, Target Health Inc., 1992N-0311\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:24:12Z", null, 0, 0, "0900006480ab4870"], ["FDA-1981-N-0114-0018", "FDA", "FDA-1981-N-0114", "Reference 5 - \"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:18:45Z", null, 0, 0, "0900006480ab42df"], ["FDA-1981-N-0114-0023", "FDA", "FDA-1981-N-0114", "Reference 14 - \"Comment No. LET22, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:22:06Z", null, 0, 0, "0900006480ab486c"], ["FDA-1981-N-0114-0028", "FDA", "FDA-1981-N-0114", "Reference 21 - \"Comment No. C2, Wholesale Druggists' Association, 1992N-0311\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:24:49Z", null, 0, 0, "0900006480ab4874"], ["FDA-1981-N-0114-0022", "FDA", "FDA-1981-N-0114", "Reference 13 - \"Comment No. LET21, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:21:19Z", null, 0, 0, "0900006480ab46f1"], ["FDA-1981-N-0114-0002", "FDA", "FDA-1981-N-0114", "Topical Acne Drug Products For Over-The-Counter Human Use; Amendment of Tenative Final Monograph", "Proposed Rule", "NPR-Notice of Proposed Rule-Making", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", "1991-10-08T03:59:59Z", "2010-03-04T23:56:04Z", null, 0, 0, "09000064805b052f"], ["FDA-1981-N-0114-0008", "FDA", "FDA-1981-N-0114", "FDA/CDER to Dockets Management Branch, August 7, 1991 - Public Administrative File for Over-The-Counter Topical Acne Drug Product Proposed Rulemaking, Docket No. 81N-0114A - Memorandum", "Other", "M-Memorandum", "2010-03-04T05:00:00Z", 2010, 3, "2010-03-04T05:00:00Z", null, "2013-07-27T23:09:56Z", null, 0, 0, "0900006480aae9d1"], ["FDA-1981-N-0114-0024", "FDA", "FDA-1981-N-0114", "Reference 15 - \"Comment No. RPT4, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:22:36Z", null, 0, 0, "0900006480ab486d"], ["FDA-1981-N-0114-0026", "FDA", "FDA-1981-N-0114", "Reference 17 - \"Comment No. C4, NDMA, 1992N-0311\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:23:37Z", null, 0, 0, "0900006480ab486f"], ["FDA-1981-N-0114-0001", "FDA", "FDA-1981-N-0114", "Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule", "Rule", "NFR-Notice of Final Rule", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2011-06-11T16:25:43Z", "2010-04424", 0, 0, "0900006480ab4db0"], ["FDA-1981-N-0114-0019", "FDA", "FDA-1981-N-0114", "Reference 10 - \"Comment No. RPT3, 1981N-0114\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:19:21Z", null, 0, 0, "0900006480ab46ee"], ["FDA-1981-N-0114-0025", "FDA", "FDA-1981-N-0114", "Reference 16 - \"Comment No. C3, American Academy of Dermatology, 1992N-0311\" - [Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human Use; Final Rule]", "Supporting & Related Material", "BKG-Background Material", "2010-03-04T05:00:00Z", 2010, 3, null, null, "2010-03-08T06:23:12Z", null, 0, 0, "0900006480ab486e"]], "truncated": false, "filtered_table_rows_count": 23, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-1981-N-0114"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114", "results": [{"value": "FDA", "label": "FDA", "count": 23, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1981-N-0114", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 14, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 6, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&document_type=Other", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&document_type=Notice", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&document_type=Proposed+Rule", "selected": false}, {"value": "Rule", "label": "Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&document_type=Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114", "results": [{"value": 2010, "label": 2010, "count": 22, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&posted_year=2010", "selected": false}, {"value": 2020, "label": 2020, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&posted_year=2020", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1981-N-0114&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 47.52795398235321, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}